Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Woven EndoBridge Device for Ruptured vs. Unruptured Aneurysms: Insights from the WorldWideWEB Study
Dugar, Franja, Essibayi, Muhammed Amir, Adeeb, N, Algin, Oktay, Ghozy, Sherief, Guenego, Adrien, Renieri, Leonardo, Saliou, G, Shotar, Eimad, Möhlenbruch, Markus, Kral, Michael , Chung, Charlotte, Salem, Mohamed M , Cancelliere, Nicole M., Diestro, Jose Danilo Bengzon, Foreman, Paul M. , Shaikh, Hamza, Župančić, Vedran , Waqas, M, Ayberk, Gıyas , Rabinov, James D. , Maingard, Julian , Schirmer, Clemens M., Piano, M, Michelozzi, Caterina , Starke, Robert M., Hassan, A. E., Ogilvie, Mark, Jones, Jesse, Brinjikji, Waleed , Psychogios, Marios, Nawka, Marie Teresa , Fiehler, Jens, Nguyen-Kim, Thi Dan Linh, Pukenas, Bryan , Burkhardt, J. David, Huynh, Thien, Martinez-Gutierrez, Juan Carlos, Sheth, S, Slawski, Diana , Lubicz, Boris , Puri, A, Raz, E, Griessenauer, Christoph J., Asadi, Hamed, Siddiqui, Adnan, Levy, Elad I, Haranhalli, Neil , Altschul, David, Ducruet, Andrew F. , Regenhardt, Robert W., Stapleton, Christopher J. , Kan, Peter , Lylyk, Pedro, Boddu, Srikanth, Knopman, Jared, Tjoumakaris, Stavropoula I., Cuellar-Saenz, Hugo H., Jabbour, Pascal M., Clarençon, Frédéric, Patankar, Tufail , Pereira, Vitor Mendes, Patel, Aman B., Almohammad, Mohammad, Kemmling, Andre, Dmytriw, Adam A., Diestro, Jose Danilo Bengzon , Diestro, Jose Danilo B , Dugar, Franja , Essibayi, Muhammed Amir , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Dibas, Mahmoud , Li, Yan-Lin, Algin, Oktay , Ghozy, Sherief , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo , Carnevale, Joseph, Saliou, Guillaume , Mastorakos, Panagiotis , Shotar, Eimad , Möhlenbruch, Markus , Salem, Mohamed Raafet Ben, Lylyk, Iván , Cancelliere, Nicole M , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Ayberk, Gıyas , Arslan, Muhammet , Ergun, Onur, Maingard, Julian, Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna L., Starke, Robert M., Hassan, Ameer, Ogilvie, Mark , Jones, Jesse , Zaccagna, Fulvio , Grist, James T. , Psychogios, Marios‐Nikos , Fiehler, Jens , Nguyen‐Kim, Thi Dan Linh , Burkhardt, Jan‐Karl , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Pulli, Benjamin , Panni, Pietro , Puri, Ajit S., Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J. , Asadi, Hamed , Siddiqui, Adnan H. , Levy, Elad I. , Altschul, David , Regenhardt, Robert W. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro, Knopman, Jared , Tjoumakaris, Stavropoula , Cuellar, Hugo , Jabbour, Pascal , Clarençon, Frédéric , Limbucci, Nicola , Patel, Aman B. , Almohammad, Mohammad , Kemmling, André , Scarcia, Luca , Dmytriw, Adam A. , Sporns, Peter Bernhard

Mayo Clinic

No container title available | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8939206/v1 Get It

Abstract Purpose Although the Woven EndoBridge (WEB) device is increasingly used for the treatment of wide-neck intracranial aneurysms, including in the acute rupture setting, comparative evidence assessing the impact of rupture status remains limited. This study compared angiographic, safety, and clinical outcomes between ruptured and unruptured intracranial aneurysms treated with WEB. Methods We conducted a retrospective analysis of prospectively collected data from the multicenter cohort registry WorldWideWEB, including consecutive adult patients with intracranial aneurysms treated with the WEB. Patients were stratified into groups of ruptured and unruptured aneurysms. Propensity score matching was used to balance baseline characteristics between both groups. Retreatment rate was the primary outcome. Secondary outcomes included mRS, safety events (thromboembolic complications) and angiographic outcomes (periprocedurally and last follow-up). Results Among 1,220 patients, 342 (28.0%) presented with ruptured aneurysms. There was no significant difference in the rate of thromboembolic complications between groups (11.8% vs 5.9%, p = 0.056). At follow-up, adequate occlusion was lower (82.2% vs 93.3%, p < 0.002) and functional outcomes were worse (mRS ≥2 in 34.1% vs 21.9%, p = 0.012) among patients with ruptured aneurysms. Periprocedural adequate occlusion (53.3% vs 53.8%, p>0.9) and retreatment rates (11.8% vs 7.1%, p = 0.14) did not differ between groups after matching. Conclusion Ruptured aneurysms demonstrated expected inferior follow-up functional and angiographic outcomes when compared with unruptured aneurysms, but no difference in retreatment rate and procedural safety. These findings support WEB as a safe and effective treatment option for appropriately selected ruptured intracranial aneurysms in routine clinical practice.
FDG-PET imaging to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy: A predictive model using penalized logistic regression analysis
Lavrova, Anna , Satoh, Ryota , Tosakulwong, Nirubol , Weigand, Stephen D. , Jack, Clifford R., Petersen, Ronald C., Reichard, R. Ross, Prudencio, Mercedes , Petrucelli, Leonard, Dickson, Dennis W., Lowe, Val, Whitwell, Jennifer L., Josephs, Keith A. , Lavrova, Anna , Josephs, Keith A , Prudencio, Mercedes , Satoh, Ryota , Jack, Clifford R. , Petersen, Ronald C. , Nguyen, Aivi T. , Reichard, R. Ross , Petrucelli, Leonard , Dickson, Dennis W. , Lowe, Val J. , Whitwell, Jennifer L.

Mayo Clinic

Journal of Alzheimer’s Disease | March 13, 2026 | Volume: 110 | Issue: 3 | Pages: 1086-1098

10.1177/13872877261421241 | PMID 41823675 Get It

Background TAR DNA-binding protein 43 (TDP-43) proteinopathy contributes to Alzheimer's disease progression, but diagnosis remains autopsy-dependent. Objective This study aimed to develop a predictive model using FDG-PET imaging to identify brain regions associated with TDP-43 pathology in vivo. Methods Penalized logistic regression analyzed data from 294 participants and a subset of 159 with Braak and Thal ≥4. Features included FDG standard uptake value ratios (SUVRs) from 123 brain regions and age. Participants were split into training (90%) and testing (10%) datasets, with significant predictors identified by non-zero coefficients at optimal lambda. Results The model achieved 68% accuracy (AUC = 0.70) in 294 participants, highlighting the middle temporal gyrus, parahippocampal gyrus, and hippocampus. In the subset (n = 159), accuracy was 65% (AUC = 0.71), with the medial amygdala and precentral gyrus as key predictors of TDP-43 pathology. Conclusions This study suggests a moderate predictive accuracy of FDG-PET to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy.
Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab
Okano, N., Pirozzi, Angelo, O'Donnell, C., Hayashi, Masato, Usón, Pedro Luiz Serrano, Hoyek, Celine , Abidoye, Oluseyi , Eslinger, Cody , Zheng-Lin, Binbin , Elliott, Natalie , Zhou, Yumei , Ahn, Daniel, Wu, Christina, Nishioka, Mariko, Sato, Taro , Teixeira, Maria Fernanda , Sforzin, Isabella, Babiker, Hani M., Tran, Nguyen H., Rimassa, Lorenza, Nagashima, Fumio, Bekaii-Saab, Tanios, Borad, Mitesh J., Usón, Pedro Luiz Serrano , O'Donnell, C. , Uson, Pedro L S , Elliott, Natalie , O'Donnell, Conor D J , Abidoye, Oluseyi , Okano, Naohiro , Pirozzi, Angelo , Hayashi, Masato , Raupach, Elizabeth A. , Petit, Joachim L. , Ahn, Daniel H. , Sonbol, Mohamad Bassam , Babiker, Hani M. , Majeed, Umair , Tran, Nguyen H. , Rimassa, Lorenza , Nagashima, Fumio , Hironaka, Shuichi , Bekaii‐Saab, Tanios , Borad, Mitesh J.

Mayo Clinic

JCO Oncology Advances | March 12, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00126 Get It

PURPOSE For patients with advanced biliary tract cancer (BTC), cancer-related time spent in health care systems, time toxicity, represents a critical but understudied burden affecting quality of life. This study aimed to quantify time toxicity in patients receiving first-line systemic therapy and evaluate whether the addition of durvalumab to gemcitabine plus cisplatin (GC) increases health care contact time. METHODS This international, multicenter, retrospective cohort study included patients with advanced BTC seen between January 2019 and April 2024 at Mayo Clinic Enterprise (US), and between January 2021 and April 2024 at Kyorin University Hospital (Japan), and Hospital Israelita Albert Einstein (Brazil). Patients received GC plus durvalumab (GCD) or GC. Time toxicity was recorded from treatment initiation until discontinuation or last follow-up during first-line systemic therapy. Multiple regression analysis identified factors associated with high time toxicity. RESULTS Among 193 patients (102 GCD, 91 GC; median age 65 years; 50% male; 49% Eastern Cooperative Oncology Group performance status [PS] 0), median time on treatment (TOT) was 156 days (95% CI, 122 to 190). The median proportion of total time toxicity was 14.4% (IQR, 10.9-20.6). Planned visits accounted for 11.9%, while unplanned visits were infrequent (1.8%). Time toxicity strongly correlated with TOT ( r = 0.824) and progression-free survival ( r = 0.827). Despite longer treatment in the GCD group than the GC group (212 v 134 days; P = .027), total time toxicity was similar (27 v 18 days; P = .19). Younger age and poor PS were independent factors of higher time toxicity. CONCLUSION Time toxicity represents a meaningful metric that allows for more comprehensive integration of the net benefit in patients with advanced BTC with a limited lifespan.
Sex differences in familial risk and genetic components of suicide attempts: a register-based cohort study in Sweden
Nguyen, Thuy-Dung, Gong, Tong , Hu, Kejia , Kuja-Halkola, Ralf , Borges, Karen, Butwicka, Agnieszka , Brikell, I., Crowley, J J, Chang, Zheng , D’Onofrio, Brian M, Lichtenstein, P., Rück, Christian, Bulik, C. M., Sullivan, Patrick, Lu, Yi , Dung, Nguyen Thi Thuy , Kuja‐Halkola, Ralf , Brikell, Isabell , D’Onofrio, Brian M. , Nguyen, Thuy-Dung , Brikell, Isabell , Rück, Christian , Lu, Yi , Crowley, James J. , Chang, Zheng , Larsson, Henrik B. W. , Lichtenstein, Paul , Bulik, Cynthia Marie , Fang, Fang, Sullivan, Patrick

Mayo Clinic

BMJ Mental Health | March 11, 2026 | Volume: 29 | Issue: 1 | Pages: e302082

10.1136/bmjment-2025-302082 | PMID 41806974 Get It

Background Suicidal behaviour shows notable sex differences, and understanding whether genetic factors contribute to these differences is critical for identifying at-risk individuals and prevention. Objective We aim to investigate the genetic contribution to suicide attempts and examine whether genetics account for sex differences in incidence. Methods This population-based cohort study includes 3.1 million individuals born 1963–1998 and followed through Swedish National Registers, including hospitals and specialist outpatient diagnoses and cause of death data. Suicide attempts were identified using ICD codes, indicating intentional self-harm, self-harm using lethal methods or leading to hospitalisation, or resulting in death. Familial aggregation, coaggregation, pedigree heritability and genetic correlations were estimated using genealogical data. For sex-specific analyses, we examined mother–daughter, female sibling, father–son and male sibling pairs, separately. Findings Suicide attempts were more common among females than males (3.3% vs 2.6%). In both sexes, risk aggregated within families (ORs ranged 1.6–3.4 across relative types) and was higher in first-degree than second-degree relatives. Familial aggregation was stronger in females than in males, and in same-sex first degree relatives compared with cross-sex pairs. Pedigree heritability was 41.9% (95% CI 36.0 to 48.4%) and did not differ significantly by sex (female 51.4% (95% CI 40.1% to 58.6%), male 45.1% (95% CI 32.3% to 52.5%), Bootstrap p value 0.40). Suicide attempt showed moderate to high pedigree genetic correlations with psychiatric disorders, strongest with substance use disorders (SUD, r g =0.85 (95% CI 0.83 to 0.96)), with no significant sex differences. The genetic correlation between female and male suicide attempts was high (0.85 (95% CI 0.80 to 0.99)), suggesting a substantial genetic overlap. Conclusions Suicide attempt has a moderate heritable component that largely overlaps between females and males and with other psychiatric disorders, particularly SUD. Stronger familial aggregation in females and in same-sex pairs highlights the potential role of sex-specific environmental or social factors. Future research should focus on non-genetic contributors and their potential interaction with genetic factors to better understand and address sex disparities in suicidal behaviour Clinical implications Genetic risk for suicide attempt is substantial but does not fully explain sex differences in incidence. Clinicians should, therefore, consider non-genetic, including sex-specific environmental and social factors, alongside family history and psychiatric comorbidity when assessing suicidal risk.
Liver Metastasectomy in Anal Squamous Cell Carcinoma: The Mayo Clinic Experience
Takacs, Noah , O’Donnell, Conor D. J., Atwell, Thomas D. , Jin, Zhaohui, Jin, Zhaohui , O'Donnell, C. , O'Donnell, Conor D J , Tran, Nguyen , Atwell, Thomas, Jin, Zhaohui , Tran, Nguyen H. , Jethwa, Krishan R. , Starlinger, Patrick

Mayo Clinic

Current Oncology | March 10, 2026 | Volume: 33 | Issue: 3 | Pages: 157

10.3390/curroncol33030157 | PMID 41892185 Get It

Background: Metastatic squamous cell carcinoma of the anus (SCCA) carries a poor prognosis, with systemic therapy remaining the standard of care. While metastasis-directed therapy improves outcomes in select gastrointestinal malignancies, the role of liver-directed intervention in metastatic SCCA remains undefined. We evaluated clinicopathologic features and oncologic outcomes of patients with liver-limited metastatic SCCA treated with curative-intent hepatic local therapy at a tertiary academic center. Methods: We conducted a retrospective cohort study of adults with histologically confirmed SCCA and liver-only metastatic disease who underwent curative-intent hepatic resection or ablation at Mayo Clinic between 1993 and 2023. Patients with extrahepatic disease or incomplete records were excluded. Demographic, tumor, treatment, and outcomes data were abstracted from electronic medical records. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Prognostic factors were assessed using univariate Cox proportional hazards models. Results: Twenty-five patients met inclusion criteria. Median age was 56.7 years, and 92% were female. Most patients had metachronous metastases (76%), a single hepatic lesion (56%), and unilobar disease (76%). Pre-intervention systemic therapy was administered in 52% of patients, with radiographic complete or partial responses observed in all treated patients. Liver-directed therapy consisted of surgical resection in 80% and thermal ablation in 20%. Among surgical patients, 90% achieved microscopically negative margins. With a median follow-up of 22 months, disease recurrence occurred in 80% of patients, most commonly within the liver. Median DFS was 7.27 months. Median OS from the date of liver-directed therapy was 51.3 months. On univariate analysis, poorly differentiated tumor histology was associated with inferior OS (hazard ratio 4.67, p = 0.018). No other clinicopathologic variables were significantly associated with DFS or OS. Conclusions: In this single-institution experience, carefully selected patients with liver-limited metastatic SCCA undergoing curative-intent hepatic-directed therapy achieved prolonged overall survival, substantially exceeding historical outcomes with systemic therapy alone. Despite frequent recurrence, the observed median OS exceeding four years supports consideration of liver-directed therapy within a multidisciplinary framework for patients demonstrating favorable disease biology and response to systemic treatment. Prospective studies are needed to better define patient selection and optimal integration of local and systemic therapies in the modern treatment era.
AXIN1 Mutated Hepatocellular Carcinoma
Torbenson, Michael, McCabe, Chantal E. , Hohenstein, Jessica D. , O’Brien, Daniel, Chen, Zongming Eric, Wu, Tsung‐Teh, Kakar, Sanjay, Tran, Nguyen H., Wang, Chen, Torbenson, Michael , Kakar, Sanjay , Wang, Chen

Mayo Clinic

American Journal of Surgical Pathology | March 10, 2026 | Volume: 50 | Issue: 6 | Pages: 642-655

10.1097/pas.0000000000002528 | PMID 41804058 Get It

CTNNB1- mutated hepatocellular carcinomas are characterized by a distinctive morphology and activation of the Wnt pathway. AXIN1 also plays a key role in the Wnt pathway, but the morphology of AXIN1-mutated tumors has not been examined. In addition, there are ongoing questions on the ability of AXIN1 mutations to activate the Wnt pathway in hepatocellular carcinoma. AXIN1 mutated tumors (N=18) were studied, along with control groups: CTNNB1 (N=17), APC (6), or “Other” genes in the Wnt pathway (5). Wnt pathway activation was studied by immunostains for beta-catenin and glutamine synthetase. Findings were supplemented by gene expression analysis using TCGA data. On histologic examination, the classic morphology associated with beta-catenin mutations was found in all 4 groups: 8/18 AXIN1 (44%), 10/17 CTNNB1 (59%), 4/6 APC (67%), and 1/5 Other (20%). By immunohistochemistry, Wnt pathway activation was found in 11/18 AXIN1 (61%), 15/17 CTTNB1 (88%), 6/6 APC (100%), and 5/5 (100%) of Other. In AXIN1- mutated tumors, the Wnt pathway was weakly activated. Glutamine synthetase stains also highlighted a new “progressed pattern” associated with distinct subnodules of staining. Tertiary lymphoid structures were uncommon except for cases with CTTNNB1 mutations plus additional mutations in the Wnt pathway. In summary, the classic morphology associated with CTNNB1 mutations is found in hepatocellular carcinomas with mutations in AXIN1 , APC , and other Wnt genes. AXIN1 mutated tumors have Wnt activation that is detectable but at lower levels than CTNNB1 mutated tumors. As tumors progress, their level of Wnt activation can change.
Tau PET overlap index correlation with neuropathological findings
Lim, Seokbeen , Lee, Jeyeon, Min, Paul H., Mester, Carly , Ghatamaneni, Sujala, Senjem, Matthew L., Botha, Hugo, Knopman, David S., Ramanan, Vijay K., Savica, Rodolfo, Fields, Julie A. , Machulda, Mary M., Dickson, Dennis W., Reichard, R. Ross, Graff‐Radford, Jonathan, Schwarz, Christopher G., Gunter, Jeffrey L. , Kantarci, Kejal, Boeve, Bradley, Vemuri, Prashanthi, Jones, D., Jack, Clifford R., Petersen, Ronald C., Murray, Melissa E., Lowe, Val J., Min, Hoon‐Ki , Lim, Seokbeen , Moloney, Christina M. , Mester, Carly T, Lowe, Val J , Min, Hoon-Ki Paul , Lee, Jeyeon, Senjem, Matthew L. , Botha, Hugo , Knopman, David S. , McCarter, Stuart J. , Ramanan, Vijay K. , Savica, Rodolfo , Machulda, Mary M. , Dickson, Dennis W. , Reichard, R. Ross, Nguyen, Aivi T. , Graff‐Radford, Jonathan , Schwarz, Christopher G. , Kantarci, Kejal , Boeve, Bradley, Vemuri, Prashanthi , Jones, David T. , Jack, Clifford R. , Petersen, Ronald C. , Murray, Melissa E. , Lowe, Val J.

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71241 | PMID 41795671 Get It

Abstract INTRODUCTION The tau positron emission tomography (PET) overlap index (OI) has shown promise in maximizing signal‐to‐noise for longitudinal tau PET imaging, particularly for early tau pathology, but requires validation against neuropathology. METHODS Fifty‐seven participants who underwent serial tau PET imaging (flortaucipir) and subsequent autopsy were included. Tau PET OI and standardized uptake value ratios (SUVRs) were compared across neuropathological diagnoses. RESULTS Tau PET OI showed greater concordance with neurofibrillary tangle (NFT) severity in the entorhinal cortex (a key region for Alzheimer's disease [AD] tauopathy) than SUVR, particularly in early Braak tangle stages (positivity: 52.2% for OI vs. 13.0% for SUVR). OI detected overlapping tau voxels that exhibited spatial correspondence with immunohistochemical and autoradiography measures of tau deposition across both AD and non‐AD tauopathies. DISCUSSION These findings demonstrate the enhanced capacity of OI in serial tau PET to robustly detect early and spatially localized tau pathology, supporting its application as a sensitive imaging metric in AD and select non‐AD tauopathies.
Melatonin improves postprandial hypoglycemia: an unusual presentation of insulinoma
Nguyen, Thanh, Matveyenko, Aleksey V. , Smushkin, Galina , Matveyenko, Aleksey V

Mayo Clinic

JCEM Case Reports | March 7, 2026 | Volume: 4 | Issue: 5 | Pages: No page available

10.1210/jcemcr/luag067 | PMID 42039111 Get It

Abstract Insulinoma is the most prevalent neuroendocrine tumor of the pancreas, presenting with a spectrum of neuroglycopenic symptoms. This case report describes a 64-year-old woman with primarily postprandial hypoglycemia, resulting in altered consciousness and confusion occurring several hours after meals. Continuous glucose monitoring (CGM) was used to establish the postprandial pattern of the patient's hypoglycemia, and this facilitated the confirmatory biochemical evaluation by a single blood draw done at the time of symptoms, without performing a 72-hour fast. Imaging demonstrated an 11-mm tumor in the pancreas, which was removed and confirmed to be a well-differentiated neuroendocrine tumor on histopathology. While awaiting pancreatic surgery, the patient began taking melatonin for sleep and reported an improvement in the frequency and severity of hypoglycemia symptoms, which was supported by CGM data and a robust expression of melatonin receptors on the excised tumor. This case raises interest in the role of melatonin receptor signaling in counteracting hyperinsulinemia and corresponding hypoglycemia in patients with insulinoma.
Outcomes of [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): A real-wo
Shore, Neal D., George, Daniel J., Heath, Elisabeth I. , Sartor, Alton Oliver, Nguyen, Jennifer, Patel, Jeetvan , Sawhney, Amrita , Kang, Barinder , Byrne, Clare , LaVallee, Chris , Wei, Xiao X. , Shore, Neal D. , George, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 88-88

10.1200/jco.2026.44.7_suppl.88 Get It

88 Background: The VISION (NCT03511664) and PSMAfore (NCT04689828) clinical trials have demonstrated the effectiveness of 177 Lu-PSMA-617 in patients with mCRPC who have previously received androgen receptor pathway inhibitors (ARPIs) with or without taxane-based chemotherapy. Sipuleucel-T is used for treatment of mCRPC in routine clinical practice, particularly among community urologists; however, to date, there are no data available to understand the effectiveness of 177 Lu-PSMA-617 in patients previously treated with sipuleucel-T. Methods: This was a retrospective, observational study of adult patients with a diagnosis of mCRPC who received 177 Lu-PSMA-617 between March 23, 2022, and June 27, 2025, and had a history of treatment with sipuleucel-T. Data were obtained from the PRECISION data platform, a harmonized dataset of patients with advanced prostate cancer in the US that integrates electronic health records and claims data from community, academic, urology, and medical oncology settings. The index date was the date of 177 Lu-PSMA-617 initiation. Patient characteristics and prostate-specific antigen (PSA) response rates were evaluated descriptively. Progression-free survival (PFS), defined as the time from 177 Lu-PSMA-617 initiation to disease progression or death, was analyzed using Kaplan–Meier curves. Results: A total of 290 patients met the inclusion criteria, of whom 72% were White and 12% were Black. At index, 32% of patients were treated in urology and 68% in oncology settings. The median age was 74 years, the median baseline PSA was 35.3 ng/mL (interquartile range [IQR] 10.0–99.2 ng/mL), and 57% of patients had a Gleason score of ≥8. In addition to sipuleucel-T, prior to 177 Lu-PSMA-617, 97% of patients had received ≥1 ARPI and 79% had received ≥1 taxane. The median follow-up for this cohort was 9.4 months (IQR 5.3–17.5 months). Among 144 patients with available PSA values both before and during 177 Lu-PSMA-617 treatment (representing 50% of the cohort), PSA response rates were as follows: a ≥50% reduction in PSA from baseline (PSA50) was observed in 60%, PSA80 in 42%, and PSA90 in 33% of patients. Overall, the median PFS was 15.2 months (95% confidence interval [CI] 11.6–19.4 months). Conclusions: In this real-world analysis of patients who received 177 Lu-PSMA-617 after sipuleucel-T treatment, the median PFS was similar to that observed in clinical trials, suggesting that 177 Lu-PSMA-617 can be sequenced after sipuleucel-T treatment in appropriate patients.